Bacillus velezensis DSM 33864 reduces Clostridioides difficile colonization without disturbing commensal gut microbiota composition

Up to 25% of the US population harbor Clostridioides difficile in the gut. Following antibiotic disruption of the gut microbiota, C. difficile can act as an opportunistic pathogen and induce potentially lethal infections. Consequently, reducing the colonization of C. difficile in at-risk populations...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2023-09, Vol.13 (1), p.14941-12, Article 14941
Main Authors: Larsen, Ida Søgaard, Chenaux, Megan, Collins, Fergus W. J., Mandic, Ana, Hansen, Lea B. S., Lauridsen, Caroline A. S., Haller, Rune F., Elvig-Jørgensen, Signe, Horwell, Ed, Christiansen, Jeanett, Silva, Ana, Vehreschild, Maria J. G. T., Cutting, Simon M., Roggenbuck-Wedemeyer, Michael, Kristensen, Nanna Ny
Format: Article
Language:English
Subjects:
631/326/421
692/4020/2741/2135
Animal models
Antibiotics
Bacillus velezensis
Clindamycin
Clostridioides difficile
Colonization
Feces
Humanities and Social Sciences
Intestinal microflora
Microbiota
multidisciplinary
Opportunist infection
Oral administration
Probiotics
Science
Science (multidisciplinary)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Up to 25% of the US population harbor Clostridioides difficile in the gut. Following antibiotic disruption of the gut microbiota, C. difficile can act as an opportunistic pathogen and induce potentially lethal infections. Consequently, reducing the colonization of C. difficile in at-risk populations is warranted, prompting us to identify and characterize a probiotic candidate specifically targeting C. difficile colonization. We identified Bacillus velezensis DSM 33864 as a promising strain to reduce C. difficile levels in vitro. We further investigated the effects of B. velezensis DSM 33864 in an assay including human fecal medium and in healthy or clindamycin-treated mouse models of C. difficile colonization. The addition of B. velezensis DSM 33864 to human fecal samples was shown to reduce the colonization of C. difficile in vitro. This was supported in vivo where orally administered B. velezensis DSM 33864 spores reduced C. difficile levels in clindamycin-treated mice. The commensal microbiota composition or post-antibiotic reconstitution was not impacted by B. velezensis DSM 33864 in human fecal samples, short-, or long-term administration in mice. In conclusion, oral administration of B. velezensis DSM 33864 specifically reduced C. difficile colonization in vitro and in vivo without adversely impacting the commensal gut microbiota composition.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-42128-8